Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials

References

• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–792.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–2667.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–211.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–315.
   PubMed Web of Science ®Google Scholar
• Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–611.
   PubMed Web of Science ®Google Scholar
• Editorial: Easier drug approval, at what price? New York Times June 9, 2018.
   Google Scholar
• Schuck RN, Pacanowski M, Woodcock J, et al. Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease. Nat Rev Drug Discov. 2017;17:79–80.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol. 2012;421:185–203.
   PubMed Web of Science ®Google Scholar
• Bergstrom J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005;206:224–232.
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr OB, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216:253–261.
   PubMed Web of Science ®Google Scholar
• Pras M, Prelli F, Franklin EC, et al. Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci U S A. 1983;80:539–542.
   PubMed Web of Science ®Google Scholar
• Gorevic PD, Prelli FC, Wright J, et al. Systemic Senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest. 1989;83:836–8433.
   PubMed Web of Science ®Google Scholar
• Thylen C, Wahlqvist J, Haettner E, et al. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation . EMBO J. 1993;12:743–748.
   PubMed Web of Science ®Google Scholar
• Arvidsson S, Pilebro B, Westermark P, et al. Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis- impact of sex and amyloid fibril composition. PLoS One. 2015;10:e0143456.
   PubMed Web of Science ®Google Scholar
• Schonhoft JD, Monteiro C, Plate L, et al. Peptide probes detect misfolded transthyretin oligomers in the plasma of early stage hereditary amyloidosis patients. Sci Trans Med. 2017;9:article number 7621.
   Web of Science ®Google Scholar
• Mangione PP, Verona G, Corazza A, et al. Plasminogen activation triggers transthyretin amyloidogenesis in vitro. J Biol Chem. 2018;293:14192–14199.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Kelly JW. The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains. J Mol Biol. 2016;428:4280–4297.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 2008;40:242–246.
   Google Scholar
• Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–1854.
   PubMed Web of Science ®Google Scholar
• Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in Northern Sweden. Acta Med Scand Suppl. 1976;590:1–64.
   PubMedGoogle Scholar
• Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235:479–485.
   PubMed Web of Science ®Google Scholar
• Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000;274:702–706.
   PubMed Web of Science ®Google Scholar
• Ando Y, Terazaki H, Nakamura M, et al. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation. 2004;77:345–349.
   PubMed Web of Science ®Google Scholar
• Ohya Y, Okamoto S, Tasaki M, et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today. 2011;41:1211–1218.
   PubMed Web of Science ®Google Scholar
• Sandgren O. Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Surv Ophthalmol. 1995;40:173–196.
   PubMed Web of Science ®Google Scholar
• Beirão JM, Malheiro J, Lemos C, et al. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015;22:117–122.
   PubMed Web of Science ®Google Scholar
• Maia LF, Magalhães R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015;86:159–167.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Yazaki M, Oguchi K, et al. Cerebral amyloid angiopathy in post-transplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87:773–781.
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629–9634.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Davies JL, Litchy WJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49:229–239.
   PubMed Web of Science ®Google Scholar
• Suanprasert N, Berk JL, Benson MD, et al. Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials. J Neurol Sci. 2014;344:121–128.
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7:497–508.
   PubMedGoogle Scholar
• Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802–2814.
   PubMed Web of Science ®Google Scholar
• Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Trans Res. 2013;6:1011–1020.
   PubMed Web of Science ®Google Scholar
• Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Trans Res. 2015;8:117–127.
   PubMed Web of Science ®Google Scholar
• Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III open-label study. J Neurol Sci. 2016;362:266–271.
   PubMed Web of Science ®Google Scholar
• Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016;263:916–924.
   PubMed Web of Science ®Google Scholar
• Salvi F, Volpe R, Pastorelli F, et al. Failure of tafamidis to halt progression of ala36pro ttr Oculomeningovascular amyloidosis. J Stroke Cerebrovasc Dis. 2018;27:e212–e214.
   PubMed Web of Science ®Google Scholar
• Lozeron P, Théaudin M, Mincheva Z, et al. Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20:1539–1545.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz J, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016.
   PubMed Web of Science ®Google Scholar
• Adamski-Werner SL, Palaninathan SK, Sacchettini JC, et al. Diflunisal analogues stabilize the native state of transthyretin potent inhibition of amyloidogenesis. J Med Chem. 2004;47:355–374.
   PubMed Web of Science ®Google Scholar
• Castellsague J, Riera-Guardia N, Calingaert B, et al. NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35:1127–1146.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13:236–249.
   PubMed Web of Science ®Google Scholar
• Tagoe CE, Reixach N, Friske L, et al. In vivo stabilization of mutant human transthyretin in transgenic mice. Amyloid. 2007;14:227–236.
   PubMed Web of Science ®Google Scholar
• Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013;110:9992–9997.
   PubMed Web of Science ®Google Scholar
• Sant'Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun. 2016;7:10787.
   PubMed Web of Science ®Google Scholar
• Qiang L, Guan Y, Li X, et al. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. Amyloid. 2017;24:42–51.
   PubMed Web of Science ®Google Scholar
• Dickson PW, Howlett GJ, Schreiber G. Rat transthyretin (prealbumin). Molecular cloning, nucleotide sequence, and gene expression in liver and brain. J Biol Chem. 1985;260:8214–8219.
   PubMed Web of Science ®Google Scholar
• Costa RH, Van Dyke TA, Yan C, et al. Similarities in transthyretin gene expression and differences in transcription factors: liver and yolk sac compared to choroid plexus. Proc Natl Acad Sci U S A. 1990;87:6589–6593.
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Roberts AJ, Adame A, et al. Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects. Neuroscience. 2014;275:352–364.
   PubMed Web of Science ®Google Scholar
• Choi SH, Leight SN, Lee VM, et al. Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci. 2007;27:7006–7010.
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Ye Z, Reixach N, et al. Transthyretin protects Alzheimer’s mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A. 2008;105:2681–2686.
   PubMed Web of Science ®Google Scholar
• Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16:543–552.
   PubMed Web of Science ®Google Scholar
• DeVos SL, Miller TM. Antisense oligonucleotides: treating neuro-degeneration at the level of RNA. Neurotherapeutics. 2013;10:486–497.
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–829.
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy . BMC Neurol. 2017;17:181–193.
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Benson MD, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 2016;23:148–157.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Baker BF, Witztum JL, et al. The effects of 2'-o-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther. 2017;27:121–129.
   PubMed Web of Science ®Google Scholar
• Sousa MM, Du Yan S, Fernandes R, et al. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci. 2001;21:7576–7586.
   PubMed Web of Science ®Google Scholar
• Gonçalves NP, Vieira P, Saraiva MJ. Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid. 2014;21:175–184.
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Tagoe C, Gallo G, et al. Why are some amyloidoses systemic? Does hepatic “chaperoning at a distance” prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J. 2012;26:2283–2293.
   PubMed Web of Science ®Google Scholar
• Kurian SM, Novais M, Whisenant T, et al. Peripheral blood cell gene expression diagnostic for identifying symptomatic transthyretin amyloidosis patients: male and female specific signatures. Theranostics. 2016;6:1792–1809.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.
   PubMed Web of Science ®Google Scholar
• Monteiro C, Martins da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018;25:120–128.
   PubMed Web of Science ®Google Scholar
• Gonçalves P, Martins H, Costelha S, et al. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid. 2016;23:249–253.
   PubMed Web of Science ®Google Scholar
• Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Soc Sci Med. 2018;210:2–21.
   PubMed Web of Science ®Google Scholar
• Deaton A, Cartwright N. Reflections on randomized control trials. Soc Sci Med. 2018;210:86–90.
   PubMed Web of Science ®Google Scholar
• Jiang X, Buxbaum JN, Chapman J, et al. A specific and versatile immunoassay suitable for the diagnosis of transthyretin amyloidosis (ATTR) using a wide range of biological samples. Proc.XVI International Symposium on Amyloidosis, Kumamoto Japan, 2018. Abstract PCO24.
   Google Scholar
• Van Spronsen FJ. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol. 2010;6:509–514.
   PubMed Web of Science ®Google Scholar
• Musini VM, Tejani AM, Bassett K, et al. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009;(4):CD000028.
   Google Scholar